Literature DB >> 10686067

Transduction of human GAD67 cDNA into immortalized striatal cell lines using an Epstein-Barr virus-based plasmid vector increases GABA content.

C Conejero-Goldberg1, C Tornatore, W Abi-Saab, M C Monaco, O Dillon-Carter, M Vawter, J Elsworth, W Freed.   

Abstract

The M213-20 and M213-1L cell lines were immortalized from rat striatum using the tsA58 allele of the SV40 large T antigen, contain the GAD enzyme, and produce GABA (Giordano et al., 1994, Exp. Neurol. 124:395-400). Cell lines that produce large amounts of GABA may be useful for transplantation into the brain in conditions such as Huntington's disease or epilepsy, where localized application of GABA may be of therapeutic value. We have explored the potential use of the pREP10 plasmid vector, which replicates episomally, to increase GAD expression and GABA production in M213-20 and M213-1L cells. Human GAD(67) cDNA was transfected into M213-20 and M213-1L, and subclones were isolated with hygromycin selection. Immunochemical studies showed increased GAD(67) expression compared to the parent M213-20 and M213-1L cell lines. Staining for the EBNA antigen and Southern blots demonstrated that the pREP10 plasmid was stably maintained in the cells for at least 12-15 months in culture. Several clones were isolated in which GABA concentrations were increased by as much as 4-fold (M213-1L) or 44-fold (M213-20) compared to the parent cell lines or 12-fold (M213-1L) and 94-fold (M213-20) greater than rat striatal tissue (1.678 +/- 0.4 micromol/g prot). The ability of these cells to continue to produce large amounts of GABA while being maintained in culture for extended periods suggests that similar methods might be used with human cell lines to produce cells that can be transplanted into the brain to deliver GABA for therapeutic purposes. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10686067     DOI: 10.1006/exnr.1999.7258

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  6 in total

1.  GABAergic lineage differentiation of AF5 neural progenitor cells in vitro.

Authors:  Joseph F Sanchez; Daniel R Crooks; Chun-Ting Lee; Cynthia J Schoen; Rose Amable; Xianmin Zeng; Thierry Florival-Victor; Nelly Morales; Mary E Truckenmiller; Donald R Smith; William J Freed
Journal:  Cell Tissue Res       Date:  2006-01-12       Impact factor: 5.249

Review 2.  Advances in the application of technology to epilepsy: the CIMIT/NIO Epilepsy Innovation Summit.

Authors:  Steven C Schachter; John Guttag; Steven J Schiff; Donald L Schomer
Journal:  Epilepsy Behav       Date:  2009-09       Impact factor: 2.937

3.  Intranigral transplants of a GABAergic cell line produce long-term alleviation of established motor seizures.

Authors:  Claudia G Castillo; Soledad Mendoza-Trejo; Manuel B Aguilar; William J Freed; Magda Giordano
Journal:  Behav Brain Res       Date:  2008-05-04       Impact factor: 3.332

4.  Benefits and risks of intranigral transplantation of GABA-producing cells subsequent to the establishment of kindling-induced seizures.

Authors:  Marc W Nolte; Wolfgang Löscher; Christiane Herden; William J Freed; Manuela Gernert
Journal:  Neurobiol Dis       Date:  2008-07-15       Impact factor: 5.996

Review 5.  Transplantation of GABA-producing cells for seizure control in models of temporal lobe epilepsy.

Authors:  Kerry Thompson
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

6.  Induction of the GABA cell phenotype: an in vitro model for studying neurodevelopmental disorders.

Authors:  Sivan Subburaju; Francine M Benes
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.